Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

PublicNASDAQ:EPZM
Date5/2013
Raised$60M
Post IPO Valuation

General Information

Websiteepizyme.com
Blogepizyme.com/news-...
Twitter@RobertJGould
CategoryBioTech
Employees
Founded2007
DescriptionBlood Cancer and Tumor Treatments

Offices

Cambridge, USA

People

CEO & Director
President and Chief Financial Officer
Board of Directors
Board Member
Board Member
Board of Directors
Board Member
Board Member
Show All People

Funding

TOTAL $61.5M
FUNDING TOTAL $51.5M
Series B, 10/2009
Bay City Capital
Amgen
Astellas Venture Management
MPM Capital
Kleiner Perkins Caufield & Byers
$32M
Series B, 12/2009
New Enterprise Associates
$8M
Venture Round, 6/2011
Leukemia & Lymphoma Society
$7.5M
Venture Round, 10/2011
GlaxoSmithKline
$4M
POST IPO FUNDING TOTAL $10M
Post IPO Equity, 2/2014
Celgene
$10M

Tags

Epizyme

Epizyme is a biopharmaceutical company located in Cambridge, MA, that is focused on researching treatments for blood cancer and tumors.

Founded in late 2007, the company has brought together premier academic and industry leaders to rapidly translate the exciting discoveries emerging from epigenetic research into specific programs that will produce important, novel, molecularly targeted drugs of the future.

Recent Milestones

  • Dollar
    Epizyme received $10M in Post IPO Equity funding. (2/12/14)
    Posted 2/12/14 at 8:32pm via bizjournals.com
  • Check
    Epizyme — Epizyme (EPZM) Struts Back To Wall Street, Plans $140 Million Raise (1/28/14)
    Posted 1/28/14 at 3:53am via biospace.com
  • Stock
    Went public with stock symbol NASDAQ:EPZM. (5/21/13)
    Posted 6/17/13 at 7:09pm
  • Check
    Epizyme — Epizyme receives $4M, publishes research (10/3/12)
    Posted 10/3/12 at 6:00pm via masshightech.com
  • Check
    Epizyme — Epizyme joins Celgene in $90M-plus partnership (4/26/12)
    Posted 4/26/12 at 6:13pm via masshightech.com
  • Dollar
    Epizyme received $4M in Venture Round funding. (10/14/11)
    Posted 10/14/11 at 7:04pm via epizyme.com
  • Dollar
    Epizyme received $7.5M in Venture Round funding. (6/23/11)
    Posted 6/23/11 at 8:40pm via masshightech.com
  • Check
    Epizyme — Epizyme snags $206M epigenetics deal with Eisai (3/10/11)
    Posted 3/10/11 at 7:38pm via fiercebiotech.com
  • Check
    Epizyme — has entered into a cancer therapeutics development and commercialization alliance with GlaxoSmithKline worth potentially more than $630 million in milestone payments (1/10/11)
    Posted 1/11/11 at 3:33am via masshightech.com
  • Check
    Epizyme — received $1 million research award from the Multiple Myeloma Research Foundation (1/7/11)
    Posted 1/10/11 at 6:56am via masshightech.com
  • Check
    Epizyme added Robert Gould as CEO & Director. (3/1/10)
    Posted 9/23/13 at 9:25pm
  • Dollar
    Epizyme received $8M in Series B funding. (12/8/09)
    Posted 12/8/09 at 12:45pm via fiercebiotech.com
  • Dollar
    Epizyme received $32M in Series B funding. (10/7/09)
    Posted 10/7/09 at 2:46pm via fiercebiotech.com
  • Check
    Epizyme added Kazumi Shiosaki as CEO. (1/1/07)
    Posted 8/27/13 at 1:06am

Videos

Screenshots

Epizyme screenshot
Above: Home Page
Uploaded: 12/9/09

Stock Price

Sources

  1. Epizyme pulls in $32M in VC capital, new investors (fiercebiotech.com) [edit]
  2. Epizyme amps up Series B to $40M (fiercebiotech.com) [edit]
  3. Epizyme to land $7.5M from Leukemia & Lymphoma Society (masshightech.com) [edit]
  4. Epizyme Achieves $4 Million in Pre-Clinical Milestone Payments in GlaxoSmithKline Alliance to Discover and Develop Novel HMT Therapeutics (epizyme.com) [edit]
  5. Epizyme stock up on $10M investment from partner Celgene (bizjournals.com) [edit]
  6. Three Mass. biotechs get $1M from myeloma foundation (masshightech.com) [edit]
    Epizyme enters lucrative GSK alliance (masshightech.com) [edit]
    Epizyme snags $206M epigenetics deal with Eisai (fiercebiotech.com) [edit]
    Epizyme joins Celgene in $90M-plus partnership (masshightech.com) [edit]
    Epizyme receives $4M, publishes research (masshightech.com) [edit]
    Epizyme (EPZM) Struts Back To Wall Street, Plans $140 Million Raise (biospace.com) [edit]
Edit This Page
Last Edited 2/12/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy